Compare Stocks

PharmaGap Inc. (PharmaGap) is a development-stage company. The Company is principally engaged in drug development and out-licensing of drug compounds. The Company is focused on the development of novel drugs for treatment of cancer and other human disease conditions. PharmaGap's lead drug compound, GAP-107B8, is in the pre-clinical testing stage and has shown in vitro and in vivo efficacy in selected cancer types. During the year ended December 31, 2011, the Company commenced specific programs to further elucidate information regarding the pharmacokinetics and toxicity profiles of GAP-107B8. A program to develop liposomal delivery formulations of GAP-107B8 in order to optimize the delivery and safety of the drug compound was completed during 2011. The Company is developing GAP-107B8 for first clinical trials in ovarian cancer, using the intra-peritoneal route of administration.

Pioneer Municipal High Income Fund, Inc. is a closed-ended fixed income mutual fund launched and managed by Pioneer Investment Management, Inc. It invests in the fixed income markets of the United States. The fund primarily invests in municipal securities. It seeks to invest in securities across the credit rating and maturity spectrum. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index and Barclays High Yield Municipal Bond Index. Pioneer Municipal High Income Fund, Inc. was formed on March 13, 2003 and is domiciled in the United States.

Shenzhou International Group Holdings Limited, an investment holding company, manufactures, processes, and sells knitwear products in Mainland China, European Union, the United States, Japan, and internationally. It produces and sells sportswear, casual wear, and lingerie wear. The company is also involved in the import and export of commodities; print and sale of knitwear products; aircraft leasing; and property management activities. Shenzhou International Group Holdings Limited was founded in 2000 and is based in Kowloon, Hong Kong.